Date: 2016-09-21
Type of information: Nomination
Compound:
Company: 4SC (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 21, 2016, the Supervisory Board of 4SC appointed Dr Jason Loveridge as new CEO of 4SC. Jason Loveridge accepted the appointment and will assume the position effective today. Jason Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia, and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia. He has more than 20 years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies.
Financial terms:
Latest news:
